It started with a phone call.

“Doc,” my CEO said, “do you know this doctor?”

I asked why.

“He wrote a prescription for a drug that cost $250,000 for one course.”

“You must mean $25,000,” I said.

“No,” she replied. “The insurer already paid two hundred fifty thousand dollars.”

I assumed it had to be a miracle therapy, some one-in-a-million life-saving treatment. Then she told me the name: Acthar Gel. I nearly fell out of my chair. Acthar: ACTH, adrenocorticotropic hormone, the same pituitary extract doctors used in the 1950s. And yet here it was, sold as a “specialty biologic” for multiple-sclerosis relapses, lupus, and nephrotic syndrome, for a quarter-million dollars a course. As I dug deeper into its history, regulatory loopholes, and pricing gymnastics, I found something darker than corporate greed. This was legitimized corruption: polished, credentialed, and woven into the fabric of modern medicine. A rot so deep it would put a glioblastoma to shame.

Birth and death of a drug

Acthar (repository corticotropin injection, ACTH) was first approved by the FDA in 1952. Back then, if a drug was safe, it was approved; proof of efficacy wasn’t required. The 1962 Kefauver-Harris Amendments later demanded proof of effectiveness. Acthar Gel was a simple pituitary extract suspended in gelatin for slow release. It was cheap, reasonably effective, and widely used through the 1950s-70s for MS relapses and inflammatory diseases. By the early 1980s, synthetic corticosteroids (prednisone, methylprednisolone, and dexamethasone) made ACTH obsolete. By 1995, Acthar’s rights landed with Rhône-Poulenc Rorer (later Sanofi-Aventis). Demand had vanished. In 2001, they sold it to a tiny biotech, Questcor Pharmaceuticals, for $100,000. At the time, a vial cost about $40.

The resurrection

Questcor discovered that Acthar’s 1952 FDA approval was still valid, so no new trials were required. They didn’t need to invest in science, safety, or efficacy, just marketing. A few small, unblinded “open-label” studies followed: uncontrolled, self-funded, and published in second-tier journals. A few dozen patients, a few glowing graphs, and suddenly Acthar was reborn as a “specialty biologic.” The price exploded from $40 to $34,000 a vial. Then came the masterstroke: the biologic loophole. Because Acthar was an old, animal-derived extract rather than a modern synthetic molecule, Questcor could classify it as a biologic, shielding it from generic or biosimilar competition. That regulatory label justified astronomical pricing under the pretense of complexity. To seal the monopoly, Questcor bought and buried Synacthen, the only potential synthetic ACTH rival. An obsolete hormone became a protected monopoly. In 2014, Irish pharma giant Mallinckrodt bought Questcor for $5.6 billion. The Federal Trade Commission later fined Mallinckrodt $100 million for antitrust violations, and the Department of Justice charged it with kickbacks and Medicaid rebate fraud. Mallinckrodt filed for bankruptcy twice, paid pennies on those penalties, and still sells Acthar at the same astronomical price. Ironically, in 2021 ANI Pharmaceuticals re-launched a supposed competitor, Purified Cortrophin Gel. In a normal market, prices would collapse, but here they didn’t budge. Both drugs remain stuck around $40,000 per vial.

The world’s most expensive obsolete drug

To grasp the absurdity, compare Acthar with true biologics. Drugs like Keytruda revolutionized medicine; they are complex, engineered molecules that took years of research, billions in investment, and massive clinical trials. A single dose of Keytruda, one of the world’s most advanced cancer immunotherapies, costs about $10,000. Acthar, by contrast, is a 1950s pig-pituitary extract. No recombinant technology. No modern trials. No innovation. Yet each vial sells for $30,000-40,000, though it probably costs a few hundred dollars to make.

Why doctors prescribed it

ACTH and steroids both raise cortisol. When IV Solu-Medrol became standard, there was no rational reason left to use ACTH. Questcor recruited “key opinion leaders” with grants, speaking fees, and advisory roles. Academic centers, hungry for industry funding, repeated the same slides written by corporate marketing teams. Even respected journals published ghostwritten reviews that recycled the same unfounded claims. Physicians, busy, trusting, and lulled by peer authority, parroted the rhetoric without asking if it made physiological sense. The result: a profession that recited data it never examined and prescribed drugs it didn’t understand. The shepherds were bought; the flock followed. This wasn’t ignorance; it was intellectual surrender. The tragedy of Acthar isn’t just corporate manipulation. It’s how willingly the medical profession became its amplifier. When a profession stops reasoning, it doesn’t just practice bad medicine; it practices mindless medicine. Worse, it practices soulless medicine.

Where is the outrage?

This isn’t just a pricing scandal; it’s an indictment of everyone who looked away. How did a 1950s pituitary extract become a $40,000 “biologic,” and not one major institution slam the brakes? Where were the neurologists, rheumatologists, and nephrologists who should have said: “This makes no physiological sense. I will not prescribe this drug.” Where were the academic leaders who claim to champion evidence-based medicine? Where were the insurers, the regulators, the professional societies? The silence, or rather, the complicity, is staggering. Major MS centers and university hospitals knew, or should have known, that Acthar offers no proven benefit over cheap, high-dose steroids. The data are public. The mechanism is obvious. The conclusion is unavoidable. Yet industry money flowed through “educational partnerships,” advisory boards, and research grants that shaped the opinions of key opinion leaders. A handful of influential voices lent legitimacy just by standing on a podium. That’s not medicine; that’s moral sedation. If our most “elite” physicians can be convinced that a crude ACTH extract deserves to be the world’s most expensive “biologic,” can we still call them scientists? And if they act knowingly for profit, or unknowingly out of intellectual surrender, do they still belong to a profession that calls itself noble? This isn’t gullibility. It’s decay: of mind and soul. When clinicians stop reasoning, they forfeit the right to call themselves scientists.

And if those entrusted to guard human health can’t guard their own intellect, they shouldn’t be trusted with anyone’s health.

Bharat Desai is an internal medicine and pulmonary physician.